Neoplasms

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Thyroid Neoplasms

Thyroid Diseases

Thyroid Cancer, Papillary

Endocrine System Diseases

Endocrine Gland Neoplasms

Head and Neck Neoplasms

Adenocarcinoma

Adenocarcinoma, Papillary

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Papillary Thyroid Carcinoma

Patients with differentiated thyroid cancer for whom oncogene-specific targeted therapy is planned from commercial supply or as part of a separate therapeutic trial

Patients with differentiated thyroid cancer enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing

Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND).

During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor.

Whole body scan

Supriya Behl

James Robinson

Junne Kamihara, MD

Theodore Laetsch, MD

Steven Waguespack, MD

Priya Mahajan, MD

Tyler Ketterl, MD, MS

Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.

This is an observational cohort study that will enroll patients with DTC metastatic to the lungs who will receive oncogene-specific targeted therapy as part of routine clinical care or a separate therapeutic clinical trial. After approximately 4 weeks of therapy, patients will have a whole body scan to determine the change in RAI-avidity of their tumor from baseline. Subsequent therapy will be at the discretion of the treating physician or according to the therapeutic trial on which the patient is enrolled.

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Targeted Therapy to Increase RAI Uptake in Patients With Metastatic DifferentiatedThyroid Cancer

The primary outcome measure is to determine the proportion of patients with differentiated thyroid cancer metastatic to the lungs for whom oncogene-specific, targeted therapy increases tumor RAI-avidity.

United States Department of Defense

Children's Hospital of Philadelphia

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

Symptoms and General Pathology

Multiple Myeloma

Neoplasms, Plasma Cell

Body Weight

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Steven Pans, MD

Whole body MRI with diffusion weighted imaging is a useful imaging tool

* staging and diagnosis
* therapy monitoring All patients will be scanned before and during treatment. The findings on diffusion weighted imaging will be correlated to the golden standard (computer tomography and MRI (T1 and STIR)).

Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging

Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI: What is the Added Value of Diffusion Weighted Imaging in Diagnosis and Follow-up

correlation between early treatment response and outcome of the patient by measuring apparent diffusion coefficient

Validation of whole body MRI diffusion-weighted imaging in multiple myeloma at 3 Tesla MRI: correlation of the new MRI imaging technique (diffusion weighted imaging)to standard validated imaging technique (Computer Tomography and Magnetic Resonance Imaging)

Whole body MRI with Diffusion weighted imaging is useful for treatment monitoring in multiple myeloma patients during and after therapy.

Measurement of apparent diffusion coefficient (ADC) and comparison of ADC before, during and after therapy. Correlation of ADC with clinical findings and standard MRI findings.

Universitaire Ziekenhuizen KU Leuven

Medical Doctor Radiologist

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Nervous System Diseases

Behaviors and Mental Disorders

Respiratory Tract (Lung and Bronchial) Diseases

Musculoskeletal Diseases

Skin and Connective Tissue Diseases

Kidney Diseases

Parkinsonian Disorders

Heart Diseases

Dementia

Pulmonary Embolism

Embolism

Rheumatic Diseases

Collagen Diseases

Parathyroid Diseases

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Brain Diseases

Central Nervous System Diseases

Thrombosis

Embolism and Thrombosis

Lung Diseases

Respiratory Tract Diseases

Connective Tissue Diseases

Ganglion Cysts

Synovial Cyst

Basal Ganglia Diseases

Movement Disorders

All patients will undergo scintigraphy on 2 distinct devices and the images obtained will be compared.

The scintigraphy of the patients will be carried out on 2 distinct devices and the images obtained will be compared.

Scintigraphy

Gilles METRARD, Dr

Monocentric study for the evaluation of a whole body CZT scintigraphy system.

Monocentric evaluation of performances and clinical interest of a whole body scintigraphic acquisition system with CZT digital detectors. Comparison of image quality and resolution of the new system compared to a reference one, on phantoms and during the acquisition of a wide variety of examinations.

Latest Imaging SPECT System Evaluation Phase 1

Rate of images obtaining a score greater than or equal to 4 in visual image quality analysis on a 5-point LIKERT scale.

Physical measurements of collimator performance on test object.

Centre Hospitalier Régional d'Orléans

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Targeted Therapy to Increase RAI Uptake in Metastatic DTC	NCT05024929	Papillary Thyro... Pediatric Cance... Differentiated ...	Whole body scan	0 Years -	Children's Hospital of Philadelphia
Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging	NCT01780766	Multiple Myelom...		25 Years -	Universitaire Ziekenhuizen KU Leuven
Latest Imaging SPECT System Evaluation Phase 1	NCT04704349	Rheumatic Disea... Neoplasms Parathyroid Dis... Pulmonary Embol... Heart Diseases Thyroid Disease... Kidney Diseases Dementia Parkinsonian Di...	Scintigraphy	18 Years -	Centre Hospitalier Régional d'Orléans
Targeted Therapy to Increase RAI Uptake in Metastatic DTC	NCT05024929	Papillary Thyro... Pediatric Cance... Differentiated ...	Whole body scan	0 Years -	Children's Hospital of Philadelphia
Latest Imaging SPECT System Evaluation Phase 1	NCT04704349	Rheumatic Disea... Neoplasms Parathyroid Dis... Pulmonary Embol... Heart Diseases Thyroid Disease... Kidney Diseases Dementia Parkinsonian Di...	Scintigraphy	18 Years -	Centre Hospitalier Régional d'Orléans
Targeted Therapy to Increase RAI Uptake in Metastatic DTC	NCT05024929	Papillary Thyro... Pediatric Cance... Differentiated ...	Whole body scan	0 Years -	Children's Hospital of Philadelphia

Spots Global Cancer Trial Database for whole body scan